Obesity is a complex disease and leading cause of morbidity and mortality and there are only insufficient treatment options available
New collaboration aims to develop novel peptide poly-agonists for the treatment of obesity and concomitant diseases
Gubra may receive up to EUR 240 million in upfront and success-based development and commercialization milestones plus staggered up to double-digit royalties on worldwide net sales
INGELHEIM, Germany & HØRSHOLM, Denmark -- (BUSINESS WIRE) --
Boehringer Ingelheim and Gubra announce a second collaboration and license agreement for the development of novel poly-agonist peptides to treat obesity. It will bring together Gubra’s established expertise in the design, synthesis, pharmaceutical characterization and in vivo testing of therapeutic peptides with Boehringer Ingelheim’s expertise in the research and development of innovative medicines in cardiometabolic diseases.
This second joint research and development program between Boehringer Ingelheim and Gubra builds on a successful ongoing collaboration in the obesity field, which was launched in 2017, and which has already achieved important milestones. It contributes to the growing Boehringer Ingelheim research and development stage portfolio in the obesity field.
“We look forward to expanding our productive collaboration with the Gubra team,” said Clive R. Wood, Ph.D., Corporate Senior Vice President Discovery Research at Boehringer Ingelheim. “I anticipate that these programs will help us bring much needed new treatment options for obesity patients.”
Boehringer Ingelheim has built a broad portfolio of marketed products for thromboembolic diseases, type 2 diabetes, acute stroke and myocardial infarction, hypertension and cardiovascular death risk reduction. With its extensive experience in the field and commitment to innovation, the company aims to transform the lives of people with cardiometabolic diseases.
Henrik Blou, CEO of Gubra said, “We are very pleased to enter into a second collaboration and license agreement with Boehringer Ingelheim focusing on the treatment of obesity. It is important for Gubra to find strong partners for our proprietary research programs, and our first collaboration with Boehringer Ingelheim has shown that the strengths of both companies are nicely complementary. Joining forces on this novel research program has the potential to take obesity treatment to the next level to the benefit of patients around the world.”
暑假催热上饶旅游市场
上饶市广信区总工会七一前夕走访慰问退休党员
NTT获评2022年度Gartner 全球网络服务
进口奔驰连遭三次撞击安全气囊无一弹出 给中
Expensify主办、全球唯一的会计和金融科技节
Northern Lights JV选择斯伦贝谢DELFI
Sol-Gel Technologies
江西上饶:吉利新能源加班加点保生产
必维集团“绿色产品线”服务,以专业促进可持
涪陵区人大常委会调研渝米集团农业面源污染防
GSMA:俄罗斯移动运营商将在5G部署方面领先于独
True Global Ventures 4 v
Blackstone Announces Openi
Cambridge Mechatronics的多项技
【创文进行时】常态化!上饶城管开展夜间环境
壳牌通过“开放人工智能能源倡议”推出新人工
株式会社日比野设计 刺激五感培育感受性的园
“金融e校”心贴心 奏响普惠最强音
铁路中秋小长假预计发送旅客4000万人次
Northern Data AG宣布100兆瓦美国新客户
玫琳凯在联合国性别平等全球契约论坛上推动全
交管窗口服务延伸 零距离入户送到家
LINE FRIENDS中国市场盈利增长,数字化布局正启新
HiTHIUM与TUV建立战略合作伙伴关系